2025-07-28 - Analysis Report
Okay, here's a comprehensive analysis of Merck & Co Inc (MRK), based on the data you provided.

**Report: Merck & Co Inc (MRK) Analysis**

**1. Performance Overview & Comparison to S&P 500 (VOO)**

*   **Ticker:** MRK
*   **Company:** Merck & Co Inc is a global pharmaceutical company focused on developing and manufacturing innovative medicines and vaccines.

**Key Numbers:**

*   MRK Cumulative Return: -3.23%
*   VOO Cumulative Return: 99.66%
*   Performance Gap: -102.7%

**Analysis:**

MRK's cumulative return significantly lags behind the S&P 500 (VOO). The current performance gap is -102.7%. The Relative Divergence is at the lowest end of its historical range (0.0), suggesting substantial underperformance compared to the S&P 500.

**Alpha/Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
|------------|--------|--------|---------|--------|--------|
| 2015-2017  | 5.0%   | 58.2%  | -24.0%  | -0.0   | 134.8  |
| 2016-2018  | 43.0%  | 66.4%  | 25.0%   | -0.1   | 183.1  |
| 2017-2019  | 40.0%  | 66.4%  | 11.0%   | 0.3    | 217.9  |
| 2018-2020  | 20.0%  | 66.4%  | 0.0%    | 0.3    | 196.0  |
| 2019-2021  | -1.0%  | 65.6%  | -50.0%  | 0.3    | 192.4  |
| 2020-2022  | 13.0%  | 69.5%  | 11.0%   | 0.3    | 278.6  |
| 2021-2023  | 31.0%  | 69.5%  | 13.0%   | 0.3    | 273.8  |
| 2022-2024  | -7.0%  | 69.5%  | -33.0%  | 0.2    | 249.8  |
| 2023-2025  | -55.0% | 61.4%  | -107.0% | 0.5    | 212.7  |

**Analysis:**

*   **CAGR:**  Shows significant variability over the periods. The most recent period (2023-2025) shows a substantial decline (-55.0%).
*   **MDD:** Maximum Drawdown is consistently high, indicating significant risk.
*   **Alpha:**  Recent periods show negative alpha, indicating underperformance relative to the benchmark. The 2023-2025 period is particularly concerning with -107.0% alpha.
*   **Beta:** Beta values are generally low (around 0.3 or less), suggesting MRK is less sensitive to market movements than the S&P 500.
*   **Cap(B):** Market capitalization has fluctuated but shows an overall increasing trend until the most recent period.

**2. Recent Price Action**

**Key Numbers:**

*   Current Price: 84.71
*   Previous Close: 84.11
*   Change: 0.71
*   5-Day Moving Average: 82.74
*   20-Day Moving Average: 81.95
*   60-Day Moving Average: 79.84

**Analysis:**

The stock price is above all three moving averages (5, 20, and 60 days), suggesting a short-term upward trend. The recent price increase (change of 0.71) is a positive signal.

**3. Technical Indicators & Outlook**

**Key Numbers:**

*   Market Risk Indicator (MRI): 0.3301 (Low Risk)
*   RSI: 62.16
*   PPO: 0.22
*   Hybrid Signal: cash_3%_Buy 80% of cash (160 shares - Caution - MRI:0.33)
*   Recent (20-day) Relative Divergence Change: -0.3 (Negative - Short-term decline)
*   Expected Return (%): -1151.4%

**Analysis:**

*   **MRI:** The MRI indicates Low Risk.
*   **RSI:**  The RSI is above 50, suggesting bullish momentum but not yet overbought.
*   **PPO:**  The PPO is positive, indicating that the short-term moving average is above the long-term moving average, which is a bullish sign.
*   **Hybrid Signal:**  The hybrid signal suggests a cautious buy recommendation, advising to allocate 80% of available cash (with only 3% cash remaining) to purchase 160 shares. The caution stems from the MRI level.
*   **Recent Relative Divergence Change:** The recent negative change in relative divergence confirms short-term underperformance.
*   **Expected Return:** The significantly negative expected return (-1151.4%) suggests a very pessimistic outlook for long-term outperformance relative to the S&P 500.

**4. Recent News & Events**

*   **[2025-07-25]:** Major business developments, regulatory changes, or market events.
*   **[2025-07-28]:** Analyst discussions on performance and outlook.
*   **[2025-07-24]:** Stock volatility influenced by recent news, earnings, or executive actions.
*   **[2025-07-26]:** Market experts highlight both risks and opportunities.

**Analysis:**

Recent news suggests volatility and attention on Merck's performance. It's crucial to investigate these specific news items to understand the drivers of the recent price action and analyst sentiment.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-05-02 | 2.01  | 15.53 B$   |
| 2024-11-06 | 1.25  | 16.66 B$   |
| 2024-08-05 | 2.15  | 16.11 B$   |
| 2024-05-03 | 1.88  | 15.78 B$   |
| 2025-05-02 | 1.88  | 15.78 B$   |

**Analysis:**

*   **EPS:** EPS fluctuates, with the highest value at 2.15 and the lowest at 1.25.
*   **Revenue:** Revenue also shows some fluctuation, ranging from 15.53B$ to 16.66 B$.
*   There are duplicated data at 2025-05-02

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-03-31 | $15.53B  | 77.98%        |
| 2024-12-31 | $15.62B  | 75.50%        |
| 2024-09-30 | $16.66B  | 75.51%        |
| 2024-06-30 | $16.11B  | 76.76%        |
| 2024-03-31 | $15.78B  | 77.56%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE     |
|------------|----------|---------|
| 2025-03-31 | $48.34B  | 10.51%  |
| 2024-12-31 | $46.31B  | 8.08%   |
| 2024-09-30 | $44.50B  | 7.09%   |
| 2024-06-30 | $43.58B  | 12.52%  |
| 2024-03-31 | $40.36B  | 11.80%  |

**Analysis:**

*   **Revenue:** Revenue has been relatively stable over the past five quarters, with a slight peak in Q3 2024.
*   **Profit Margin:** Profit margins are consistently high, generally above 75%, indicating strong profitability.
*   **Equity:** Equity has been steadily increasing, suggesting a growing asset base.
*   **ROE:** ROE fluctuates, with the highest value in Q2 2024, but remains healthy, indicating good returns on equity.

**7. Overall Summary**

Merck (MRK) shows a mixed picture. While recent price action and some technical indicators suggest short-term bullishness, the significant underperformance compared to the S&P 500, negative alpha, and a very negative long-term expected return are concerning. Revenue and profitability have been stable, and returns on equity have been healthy.

The key takeaway is that while the company's financials seem solid, the market is currently pricing in a significant degree of underperformance for MRK compared to the broader market. The analyst notes indicate there may be major market events impacting this valuation.

**Recommendation:**

Given the conflicting signals, a cautious approach is warranted. Investors should carefully monitor the news and company announcements to understand the factors driving the underperformance. The Hybrid Signal's cautious buy recommendation seems appropriate, but further due diligence is necessary before making any significant investment decisions.
